AstraZeneca plc (LON:AZN)‘s stock had its “buy” rating reissued by investment analysts at Citigroup Inc. in a report issued on Monday.
Other equities research analysts have also issued research reports about the stock. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a GBX 4,800 ($59.97) price objective on shares of AstraZeneca plc in a research note on Thursday, July 21st. Jefferies Group lifted their target price on shares of AstraZeneca plc from GBX 4,600 ($57.47) to GBX 4,800 ($59.97) and gave the stock a “hold” rating in a report on Thursday, July 14th. HSBC set a GBX 4,815 ($60.16) target price on shares of AstraZeneca plc and gave the stock a “neutral” rating in a report on Tuesday, August 2nd. Beaufort Securities reiterated a “hold” rating on shares of AstraZeneca plc in a report on Wednesday, August 10th. Finally, Goldman Sachs Group Inc. set a GBX 4,000 ($49.98) target price on shares of AstraZeneca plc and gave the stock a “sell” rating in a report on Wednesday, August 10th. Four equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. AstraZeneca plc presently has a consensus rating of “Hold” and a consensus target price of GBX 4,969.94 ($62.09).
Shares of AstraZeneca plc (LON:AZN) traded up 2.17% during trading on Monday, reaching GBX 4301.50. 3,255,379 shares of the company’s stock were exchanged. The company has a 50 day moving average price of GBX 4,627.08 and a 200-day moving average price of GBX 4,581.14. The company’s market capitalization is GBX 54.41 billion. AstraZeneca plc has a 52-week low of GBX 3,680.00 and a 52-week high of GBX 5,505.00.